AbCellera Biologics Inc. ABCL Equity Method Investments
Equity Method Investments at other companies
Other financials
Where this comes from
Reported directly by AbCellera Biologics Inc. in its filing.
Tagged under the XBRL concept us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount.
The source filing: AbCellera Biologics Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:28 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001703057-26-000046
At June 30, 2026, the Company also held non-marketable securities included in other long-term assets of $26.4 million (December 31, 2025 - $32.5 million), reflecting a $6.1 million impairment recognized within other income (expense) during the quarter. These non-marketable securities are measured at cost less any impairment, plus or minus changes resulting from observable price changes in orderly transactions for identical or similar investments of the same issuer.
Item 1. Financial Statements (Unaudited)
FAQ
- What is AbCellera Biologics Inc.'s equity method investments?
- AbCellera Biologics Inc. (ABCL) reported equity method investments of $26.4M in Q2 2026.
- How has AbCellera Biologics Inc.'s equity method investments changed year-over-year?
- AbCellera Biologics Inc.'s equity method investments decreased by 20.2% year-over-year, from $33.1M to $26.4M.
- What is the long-term trend for AbCellera Biologics Inc.'s equity method investments?
- Over 5 years (2020 to 2025), AbCellera Biologics Inc.'s equity method investments has grown at a 11.0% compound annual growth rate (CAGR), from $19.25M to $32.5M.
- What does equity method investments mean?
- Investments in unconsolidated affiliates and joint ventures where the company has significant influence (typically 20-50% ownership), carried at proportional book value.
Ask your AI about AbCellera Biologics Inc.'s equity method investments.
Connect your AI assistant and compare it to peers, right in your chat.
